摘要
Objective: To study the effect of antisense VEGF RNA on rat C6 gliomas in vivo and find out the feasibility ofantiangiogenesis therapy with antisense VEGF RNA formalignant gliomas. Methods: Parental rat C6 glioma cells and C6 cells transfected with antisense VEGF cDNA were implanted intracerebrally and subcutaneously into SD rats as control and transfected group. Rats bearing cerebral and subcutaneous C6 gliomas were treated with antisenseVEGF cDNA as treated group and sense VEGF cDNA and empty vector as control of treated group. The generalmanifestation, survival time, MRI and histopathologicalchanges of all rats were observed. The volume ofsubcutaneously implanted tumors was determinedregularly. In situ hybridization and immunohistochemicalstaining were used for detection of VEGF gene expression of gliomas while PCNA immunostaining and TUNELmethod for examination of proliferation activity andapoptosis of gliomas, respectively. Results: The survival of the rats in transfected and treated group was prolonged.There were two rats surviving over 90 d in the treatedgroup and their tumors disappeared. The VEGF geneexpression, the number of microvessels and theproliferation activity were decreased and a large amount of apoptotic cells could be found in cerebral and subcutaneous gliomas in treated and transfected groups. Conclusion:VEGF is one of the candidate genes for gene therapy ofmalignant gliomas. Antisense VEGF RNA combined with other therapies should be studied further for enhancing the therapeutic effect of malignant gliomas.
Objective: To study the effect of antisense VEGF RNA on rat C6 gliomas in vivo and find out the feasibility ofantiangiogenesis therapy with antisense VEGF RNA formalignant gliomas. Methods: Parental rat C6 glioma cells and C6 cells transfected with antisense VEGF cDNA were implanted intracerebrally and subcutaneously into SD rats as control and transfected group. Rats bearing cerebral and subcutaneous C6 gliomas were treated with antisenseVEGF cDNA as treated group and sense VEGF cDNA and empty vector as control of treated group. The generalmanifestation, survival time, MRI and histopathologicalchanges of all rats were observed. The volume ofsubcutaneously implanted tumors was determinedregularly. In situ hybridization and immunohistochemicalstaining were used for detection of VEGF gene expression of gliomas while PCNA immunostaining and TUNELmethod for examination of proliferation activity andapoptosis of gliomas, respectively. Results: The survival of the rats in transfected and treated group was prolonged.There were two rats surviving over 90 d in the treatedgroup and their tumors disappeared. The VEGF geneexpression, the number of microvessels and theproliferation activity were decreased and a large amount of apoptotic cells could be found in cerebral and subcutaneous gliomas in treated and transfected groups. Conclusion:VEGF is one of the candidate genes for gene therapy ofmalignant gliomas. Antisense VEGF RNA combined with other therapies should be studied further for enhancing the therapeutic effect of malignant gliomas.
